

SUPPLEMENTARY TABLE S4. 18-MONTH FAIRPARK CLINICAL TRIAL

Month	Delayed-start group				Early-start group			
	Baseline 19	6 19	12 18	18 16	Baseline 21	6 20	12 19	18 18
No of patients	24 [18.5-27]	24 [22-28.5]	22 [20.5-27]	23 [20-26]	23.5 [19.5-27.5]	22 [17-25]	22 [17-26]	22.5 [17-26.8]
UPDRS motor score	(23 ± 7)	(24 ± 6) +1.0 ± 0.73	(22.8 ± 6) -0.11 ± 0.7	(23.4 ± 7) +1.0 ± 0.7	(23.9 ± 7)	(21.6 ± 8) -2.3 ± 0.6	(21.3 ± 8) -2.1 ± 0.5	(21.5 ± 8) -1.4 ± 0.5
Change from baseline	—				—			
Change over first			-1.9 ± 0.3					
6 mo DFP treatment				+0.67 ± 0.20				+0.6 ± 0.2
Change over last								
6 mo DFP treatment								

The results of the 18-month FAIRPARK clinical trial of DFP (see Table 1) were further analyzed as a function of the changes in the UPDRS motor score from baseline or over 6-month (mo) periods. The patients in the early-start group received DFP for 18 months [between month 0 (baseline) and month 18], whereas the patients in the delayed-start group received DFP only for 12 months (between months 6 and 18). The UPDRS motor scores are expressed as the median [1st quartile-3rd quartile] and (in brackets) the mean ± SD. A covariance analysis of the mean change from baseline yielded *p*-values and effect size values (in brackets) of 0.002 (-1.1), 0.03 (-0.8), and 0.01 (-0.9) for months 6, 12, and 18, respectively. The covariance analyses of changes over specific 6-month periods of DFP treatment (*i.e.*, the first period comparing months 0-6 for the ES group with months 6-12 for the DS group and last period comparing months 12-18 for both the ES and DS groups) showed that there were no significant intergroup differences.